Home » Posts filed under Miami Dade Broward Palm Beach homecare
Showing posts with label Miami Dade Broward Palm Beach homecare. Show all posts
Showing posts with label Miami Dade Broward Palm Beach homecare. Show all posts

A Family Member HomeCare, a Ft. Lauderdale Home Health Caregiver Agency, Notes Florida's Alzheimer's Disease Advisory Committee Meets October 21, 2011 in Tallahassee

Posted by Unknown Saturday, October 1, 2011 0 comments

The Florida Alzheimer's Disease Advisory Committee next meets October 21, 2011 from 1:30 p.m. - 3:30 p.m. (EST).   Hyperlink to online:  Notice of Meeting. 

Place:  Cabot Lodge, 1653 Raymond Diehl Road, Tallahassee, Florida  32308

The Alzheimer’s Disease Advisory Committee is a 10-member panel that advises the Florida Department of Elder Affairs regarding legislative, programmatic and administrative matters that are related to Alzheimer’s disease victims and their caretakers. Committee members must be Florida residents and reflect the following representation:
◦At least four of the 10 members must be licensed pursuant to Chapter 458 or 459 or hold a Ph.D. degree and be currently involved in research of Alzheimer’s disease;
◦The 10 members must include a least four persons who have been caregivers of victims of Alzheimer’s disease;
◦Whenever possible, there should be one individual from each of the following professions: a gerontologist, a geriatric psychiatrist, a geriatrician, a neurologist, a social worker and a registered nurse.
Members are appointed to four-year staggered terms. The committee elects one of its members to serve as chair for a one-year term. Committee meetings are held quarterly or as frequently as needed.

Committee Members as of April 2011
Jamie Glavich - Chairperson
9664 Hood Road
Jacksonville, FL 32223
Phone: 904-292-9600
Fax: 904-292-0956
Todd Golde
1275 Center Drive, #BMS J-485
Gainsville, FL 32610
Phone: 352-273-9456
Fax: 352-294-5060

Jaroslaw Koberda, M.D., Ph.D.
1818 Miccosukee Commons Dr.
Tallahassee, FL 32308
Phone: 850-459-8263
Fax: 850-877-3086

Karl Dhana, M.D.
4847 Fred Gladstone Drive
West Palm Beach, FL 33417
Phone: 561-687-5768
Fax: 561-687-0885

Huntington Potter, Ph.D.
4001 East Fletcher Avenue
Tampa, FL 33613
Phone: 813-866-1600
Fax: 813-866-1601
 
Martha Purdy, MSW, LCSW
1506 Lake Highland Drive
Orlando, FL 32803
Phone: 407-843-1910
Fax: 407-381-4155
Christine Powers
12417 Clock Tower Parkway
Hudson, FL 34667
Phone: 727-863-6868
Fax: 727-869-7057

Bruce Robinson, M.D.
5880 Rand Blvd., #205
Sarasota, FL 34238
Phone: 941-917-7197
Fax: 941-917-4016

Peggy Connelly
3205 Astor Avenue
Vero Beach, FL 32966
Phone: 727-644-6314

Frank Webbe, Ph.D.
150 W. University Boulevard,
Melbourne, FL 32901,
Phone: 321-674-8086
 
Role of the Alzheimer's Disease Advisory Committee:

Pursuant to Section 430.501 (3) Florida Statutes, the Governor of the State of Florida also appoints a ten member Alzheimer's Disease Advisory Committee to advise the Department of Elder Affairs.

(a) The committee membership shall be representative as follows:
1. At least 4 of the 10 members must be licensed pursuant to chapter 458 or chapter 459 or hold a Ph.D. degree and be currently involved in the research of Alzheimer's disease.
2.The 10 members must include at least 4 persons who have been caregivers of victims of Alzheimer's disease.
3.Whenever possible, the 10 members shall include 1 each of the following professionals: a gerontologist, a geriatric psychiatrist, a geriatrician, a neurologist, a social worker, and a registered nurse.
Function of the Committee
(b) The function of the Advisory Committee is to advise DOEA in the performance of its duties under the ADI. As appropriate, and with the approval of DOEA, the Advisory Committee may establish subcommittees.
 
--------------------------------------------------------------------------------

Florida Administrative Code

CHAPTER 58D-1


ADMINISTRATION OF THE ALZHEIMER'S DISEASE INITIATIVE

58D-1.001 Purpose
58D-1.002 Definitions
58D-1.003 Eligibility
58D-1.004 Program Components
58D-1.005 Program Administration
58D-1.006 Service Provider Responsibilities
58D-1.007 Program Forms
58D-1.001 Purpose.

The purpose of these rules is to provide a framework by which the Department of Elder Affairs will administer Sections 430.501 through 430.504, F.S., the Alzheimer’s Disease Initiative. The Alzheimer’s Disease Initiative (ADI) was established by the Legislature in 1985 to provide services and training to address the special needs of individuals suffering from Alzheimer’s disease and related memory disorders and their caregivers. It also provides for research relating to the cause, prevention, management, and treatment of the disease.

Specific Authority 430.08 FS. Law Implemented 430.04, 430.501, 430.502, 430.503, 430.504 FS. History–New 3-28-95, Amended 9-24-08.



58D-1.002 Definitions.

The following terms are defined in this rule:

(1) Alzheimer’s Disease Advisory Committee: The committee created pursuant to Section 430.501(2), (3), F.S., to advise the department in the performance of its duties pursuant to the ADI.

(2) Alzheimer’s Disease and Related Disorders (ADRD) Research Brain Bank: The entity designated by the department to collect post mortem normal control brains and brains of individuals who were clinically diagnosed as having Alzheimer’s disease for the purpose of conducting comparative research aimed at learning about, finding a cause, and developing a treatment or cure for the disease.

(3) Client: The person with ADRD; however, the client’s caregiver will receive benefits through the provision of education, training, respite, and support services, as needed.

(4) Memory Disorder Clinic: Research oriented programs created pursuant to Sections 430.502(1) and (2), F.S., to provide diagnostic and referral services, conduct basic and service-related multidisciplinary research, and develop training materials and educational opportunities for lay and professional caregivers of individuals with Alzheimer’s disease. Memory disorder clinics shall provide:

(a) A minimum of four (4) hours of in-service training annually to model day care and respite care providers in the designated service area; and

(b) A minimum of one (1) annual contact with each model day care and respite care provider in the designated service area to plan and develop service-related research projects.

(5) Model Day Care Program: Refers to the three specialized day care programs specifically authorized by Section 430.502(4), F.S. These programs provide a therapeutic setting for the provision of specialized services to clients with Alzheimer’s disease. They also provide training to health care and social service personnel and caregivers, and serve as a natural laboratory for research.

(6) Related Memory Disorders: Other forms of progressive cognitive disorders that result in diminished memory, language, other cognitive functions, and the inability to perform activities of daily living.

(7) Research: Investigations undertaken to determine the cause, resulting behavioral changes, treatment, cure, and impact of ADRD.

(8) Training: The provision of educational activities and instruction to assist health care professionals, social service providers, and caregivers in understanding ADRD and to increase their knowledge and caregiving skills.

Specific Authority 430.08 FS. Law Implemented 430.501-.502 FS. History–New 3-28-95, Amended 9-24-08.



58D-1.003 Eligibility.

(1) To be eligible for model day care services, an individual must be at least 18 years of age and have a diagnosis of Alzheimer’s disease or a related memory disorder.

(2) To be eligible to receive all other services funded under the Alzheimer’s disease Initiative that are included in the provider’s contract with the department or the area agency on aging, an individual must be 18 years of age or older and have a diagnosis of Alzheimer’s disease or related memory disorder, or be suspected of having Alzheimer’s disease or a related memory disorder.

(3) The caregivers of individuals receiving services under the Alzheimer’s Disease Initiative are eligible to receive training and related support services to assist them in caring for the person with ADRD.

Specific Authority 430.08 FS. Law Implemented 430.501-.502 FS. History–New 3-28-95, Amended 9-24-08.



58D-1.004 Program Components.

(1) In its role as advisor to the department, the Alzheimer’s Disease Advisory Committee shall provide feedback for each of the following components:

(a) Memory Disorder Clinics;

(b) Brain Bank;

(c) Model Day Care; and

(d) Respite Care.

(2) The Alzheimer’s Disease Advisory Committee shall address service, training, research, and coordination among components.

(3) The Alzheimer’s Disease Advisory Committee may enlist services, assistance, and direction from a broad representation of health care professionals, service providers, individuals affiliated with the Alzheimer’s Association and the provision of Alzheimer’s community care, dementia specific service providers, caregivers, and other interested or knowledgeable parties.

Specific Authority 430.08 FS. Law Implemented 430.501-.502 FS. History–New 3-28-95, Amended 9-24-08.



58D-1.005 Program Administration.

(1) The Department of Elder Affairs shall plan, develop and coordinate a statewide program to carry out its responsibilities under the Alzheimer’s Disease Initiative.

(2) The area agency on aging, under contract with the department, shall be responsible for the planning and administration of respite and model day care services funded under the Alzheimer’s Disease Initiative and shall contract with local service providers for the provision of these services. Each area agency on aging shall:

(a) Comply with State of Florida procedures regarding solicitation and execution of agreements with providers of services.

(b) Maintain coordination with the memory disorder clinics, the Alzheimer’s Disease Brain Bank, and all other components of the Alzheimer’s Disease Initiative in the designated planning and service area as outlined in its contract with the department.

(c) Comply with all terms and conditions of its contract with the department.

Specific Authority 430.08 FS. Law Implemented 430.502-.503 FS. History–New 3-28-95, Amended 10-30-05, 9-24-08.



58D-1.006 Service Provider Responsibilities.

Each service provider must:

(1) Establish service priorities and coordinate the delivery of services to clients.

(2) Employ competent and qualified staff to provide the services essential to the achievement of program goals and objectives as specified in its contract with the department or the area agency on aging.

(3) Maintain the minimum staffing requirements established in its contract with the department or area agency on aging.

(4) Provide case management services as applicable and as specified in its contract with the department or area agency on aging.

(5) Provide respite or model day care services, and maintain coordination with the memory disorder clinics and the brain bank as specified in its contract with the department or area agency on aging.

(6) Provide pre-service and in-service training for staff and volunteers as specified in its contract with the department or area agency on aging.

(7) Monitor subcontract providers to assure quality of service delivery.

(8) Make payments to subcontractors.

(9) Collect co-payments for services pursuant to Section 430.503(2), F.S. Co-payments must be determined pursuant to Rule 58C-1.007, F.A.C.

(10) Maximize the use of volunteers in service delivery.

(11) Develop and implement procedures for client appeals.

(12) Ensure that quality services are delivered to clients and caregivers.

(13) Maintain client and program records and provide reports as required by its contract with the department or area agency on aging.

(14) Establish goals and objectives for the Alzheimer’s Disease Initiative research component and submit reports as specified by the department on research activities.

Specific Authority 430.08 FS. Law Implemented 430.502-.503 FS. History– New 3-28-95, Amended 9-24-08.


58D-1.007 Program Forms.

The forms used for programs regulated by this chapter are incorporated by reference in Rule 58A-1.010, F.A.C. In addition, a care plan must be developed that meets the criteria established in subsection (3) of that rule.

Specific Authority 430.08 FS. Law Implemented 430.502 FS. History–New 8-20-00, Amended 8-6-01, 9-24-08.



Brian Gauthier's A Family Member HomeCare, a Hollywood and Boca Raton caregiver agency serving Miami-Dade, Broward and Palm Beach County, providing Home Health, Home Health Care, Home Health Care Agency, Homecare, In-Home Caregiver, Home Nursing Care, Skilled Nursing, Certified Nursing Assistant, Home Health Aides, Home Health Aide, Senior Companion, Hollywood Home Health Care, Ft. Lauderdale Home Health Care, Miramar Home Health Care, Pembroke Pines Home Health Care, Hallandale Beach Home Health Care, Dania Beach Home Health Care, Cooper City Home Health Care, Fort Lauderdale Home Health Care Agency, Plantation Home Health Care, Weston Home Health Care, Bonaventure Home Health Care, Galt Ocean Mile Home Health Care, Imperial Point Home Health Care, Sunrise Home Health Care, Margate Home Health Care, Lauderhill Home Health Care, Lauderdale Lakes Home Health Care, Medicare Home Health Care, Medicare Home Health Care Agency, Dementia Care Services, Alzheimer's Home Health Care, Coconut Creek Home Health Care, West Park Home Health Care, Coral Springs Home Health Care, Parkland Home Health Care, Deerfield Beach Home Health Care, Pompano Beach Home Health Care, Hillsboro Beach Home Health Care, Lighthouse Point Home Health Care,King's Point Home Health Care, John Knox Village Home Health Care, Palm Aire Home Health Care, Lauderdale by the Sea Home Health Care, Oakland Park Home Health Care, Southwest Ranches Home Health Care, Sea Ranch Lakes Home Health Care, Aventura Home Health Care, Sunny Isles Beach Home Health Care, Surfside Home Health Care, Bahia Mar Home Health Care, Boca Raton, Delray Beach Home Health, Broward Alzheimer's Care, Ft. Lauderdale Dementia Care,
Location: Deerfield Beach, FL, USA

A Family Member HomeCare, A Hollywood and Boca Raton Florida Cautions that Ft. Lauderdale Seniors With Dementia Diagnosis Should Note Alzheimer’s diagnostic guidelines updated for first time in decades

Posted by Unknown 0 comments




Alzheimer’s diagnostic guidelines updated for first time in decades


For more information: http://www.nia.nih.gov/Alzheimers/Resources/diagnosticguidelines.htm


NIH-supported revision also proposes staging of disease, potential use of biomarkers


The National Institutes of Health announced in April 2011 that, for the first time in 27 years, clinical diagnostic criteria for Alzheimer’s disease dementia have been revised, and research guidelines for earlier stages of the disease have been characterized to reflect a deeper understanding of the disorder. The National Institute on Aging/Alzheimer’s Association Diagnostic Guidelines for Alzheimer’s Disease outline some new approaches for clinicians and provide scientists with more advanced guidelines for moving forward with research on diagnosis and treatments. They mark a major change in how experts think about and study Alzheimer’s disease. Development of the new guidelines was led by the National Institutes of Health and the Alzheimer’s Association.


The original criteria were the first to address the disease and described only later stages, when symptoms of dementia are already evident. The updated guidelines announced today cover the full spectrum of the disease as it gradually changes over many years. They describe the earliest preclinical stages of the disease, mild cognitive impairment, and dementia due to Alzheimer’s pathology. Importantly, the guidelines now address the use of imaging and biomarkers in blood and spinal fluid that may help determine whether changes in the brain and those in body fluids are due to Alzheimer’s disease. Biomarkers are increasingly employed in the research setting to detect onset of the disease and to track progression, but cannot yet be used routinely in clinical diagnosis without further testing and validation.


“Alzheimer’s research has greatly evolved over the past quarter of a century. Bringing the diagnostic guidelines up to speed with those advances is both a necessary and rewarding effort that will benefit patients and accelerate the pace of research,” said National Institute on Aging Director Richard J. Hodes, M.D.


“We believe that the publication of these articles is a major milestone for the field,” said William Thies, Ph.D., chief medical and scientific officer at the Alzheimer’s Association. “Our vision is that this process will result in improved diagnosis and treatment of Alzheimer’s, and will drive research that ultimately will enable us to detect and treat the disease earlier and more effectively. This would allow more people to live full, rich lives without—or with a minimum of—Alzheimer’s symptoms.”


The new guidelines appear online April 19, 2011 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. They were developed by expert panels convened last year by the National Institute on Aging (NIA), part of the NIH, and the Alzheimer’s Association. Preliminary recommendations were announced at the Association’s International Conference on Alzheimer’s Disease in July 2010, followed by a comment period.


Guy M. McKhann, M.D., Johns Hopkins University School of Medicine, Baltimore, and David S. Knopman, M.D., Mayo Clinic, Rochester, Minn., co-chaired the panel that revised the 1984 clinical Alzheimer’s dementia criteria. Marilyn Albert, Ph.D., Johns Hopkins University School of Medicine, headed the panel refining the MCI criteria. Reisa A. Sperling, M.D., Brigham and Women’s Hospital, Harvard Medical School, Boston, led the panel tasked with defining the preclinical stage. The journal also includes a paper by Clifford Jack, M.D., Mayo Clinic, Rochester, Minn., as senior author, on the need for and concept behind the new guidelines.


The original 1984 clinical criteria for Alzheimer’s disease, reflecting the limited knowledge of the day, defined Alzheimer’s as having a single stage, dementia, and based diagnosis solely on clinical symptoms. It assumed that people free of dementia symptoms were disease-free. Diagnosis was confirmed only at autopsy, when the hallmarks of the disease, abnormal amounts of amyloid proteins forming plaques and tau proteins forming tangles, were found in the brain.


Since then, research has determined that Alzheimer’s may cause changes in the brain a decade or more before symptoms appear and that symptoms do not always directly relate to abnormal changes in the brain caused by Alzheimer’s. For example, some older people are found to have abnormal levels of amyloid plaques in the brain at autopsy yet never showed signs of dementia during life. It also appears that amyloid deposits begin early in the disease process but that tangle formation and loss of neurons occur later and may accelerate just before clinical symptoms appear.


To reflect what has been learned, the National Institute on Aging/Alzheimer’s Association Diagnostic Guidelines for Alzheimer’s Disease cover three distinct stages of Alzheimer’s disease:


•Preclinical – The preclinical stage, for which the guidelines only apply in a research setting, describes a phase in which brain changes, including amyloid buildup and other early nerve cell changes, may already be in process. At this point, significant clinical symptoms are not yet evident. In some people, amyloid buildup can be detected with positron emission tomography (PET) scans and cerebrospinal fluid (CSF) analysis, but it is unknown what the risk for progression to Alzheimer’s dementia is for these individuals. However, use of these imaging and biomarker tests at this stage are recommended only for research. These biomarkers are still being developed and standardized and are not ready for use by clinicians in general practice.
•Mild Cognitive Impairment (MCI) – The guidelines for the MCI stage are also largely for research, although they clarify existing guidelines for MCI for use in a clinical setting. The MCI stage is marked by symptoms of memory problems, enough to be noticed and measured, but not compromising a person’s independence. People with MCI may or may not progress to Alzheimer’s dementia. Researchers will particularly focus on standardizing biomarkers for amyloid and for other possible signs of injury to the brain. Currently, biomarkers include elevated levels of tau or decreased levels of beta-amyloid in the CSF, reduced glucose uptake in the brain as determined by PET, and atrophy of certain areas of the brain as seen with structural magnetic resonance imaging (MRI). These tests will be used primarily by researchers, but may be applied in specialized clinical settings to supplement standard clinical tests to help determine possible causes of MCI symptoms.
•Alzheimer’s Dementia – These criteria apply to the final stage of the disease, and are most relevant for doctors and patients. They outline ways clinicians should approach evaluating causes and progression of cognitive decline. The guidelines also expand the concept of Alzheimer’s dementia beyond memory loss as its most central characteristic. A decline in other aspects of cognition, such as word-finding, vision/spatial issues, and impaired reasoning or judgment may be the first symptom to be noticed. At this stage, biomarker test results may be used in some cases to increase or decrease the level of certainty about a diagnosis of Alzheimer’s dementia and to distinguish Alzheimer’s dementia from other dementias, even as the validity of such tests is still under study for application and value in everyday clinical practice.


The panels purposefully left the guidelines flexible to allow for changes that could come from emerging technologies and advances in understanding of biomarkers and the disease process itself.


“The guidelines discuss biomarkers currently known, and mention others that may have future applications,” said Creighton H. Phelps, Ph.D., of the NIA Alzheimer’s Disease Centers Program. “With researchers worldwide striving to develop, validate and standardize the application of biomarkers at every stage of Alzheimer’s disease, we devised a framework flexible enough to incorporate new findings.”


###


The Alzheimer's Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Their mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. For more information on the Association, visit http://www.alz.org/.


For more information on the new diagnostic criteria and links to the papers referenced below, visit www.alz.org/research/diagnostic_criteria. Media contact is Niles Frantz at 312-335-5777 or niles.frantz@alz.org.


The National Institute on Aging leads the federal government effort conducting and supporting research on aging and the health and well being of older people. The NIA provides information on age-related cognitive change and neurodegenerative disease specifically at its Alzheimer’s Disease Education and Referral (ADEAR) Center at www.nia.nih.gov/Alzheimers For more on health and on aging generally, go to http://www.nia.nih.gov/. To sign up for e-mail alerts about new findings or publications, please visit either website.


About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.


References:

•Clifford R. Jack Jr., et al. “Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer’s Association Workgroups.”
•Guy M. McKhann and David S. Knopman, et al. “The Diagnosis of Dementia due to Alzheimer’s Disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association Workgroup.”
•Marilyn S. Albert, et al. “The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging and Alzheimer’s Association Workgroup.”
•Reisa A. Sperling, et al. “Toward Defining the Preclinical Stages of Alzheimer’s Disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association Workgroup.”


More information is below:
Journal articles about the updated guidelines, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association:


A Family Member HomeCare of Hollywood & Boca Raton, Florida is a Broward, Miami-Dade and Palm Beach County Home Health Care Agency Serving Coconut Creek, Cooper City, Coral Springs, Dania, Davie, Deerfield, Ft. Lauderdale, Hallandale, Hillsboro, Hollywood, Lauderdale Lakes, Lauderdale-by-the-Sea, Lauderhill, Lighthouse Point, Margate, Miramar, North Lauderdale, Oakland Park, Parkland, Pembroke Park, Pembroke Pines, Plantation, Pompano, Sea Ranch Lakes, Southwest Ranches, Sunrise, Tamarac, Weston, Wilton Manors, Aventura, Hialeah, North Miami, Miami Lakes, Sunny Isles, Bal Harbour, Surfside, Boynton, Lake Worth & Delray With Comprehensive Home Health Care, In-Home Caregivers, Nursing & Home Health Aides for Seniors, Elderly, Disabled, Dementia & Alzheimer’s Patients. Joint Commission Accredited, Licensed, Bonded, Insured
Location: Coral Springs, FL, USA

Copyright © 2012 A Family Member HomeCare Blog. All rights reserved.

Super SEO created by Blogger Tuts | Published by GalleryBloggerTemplates.com